









Markets
/
Stocks
/
nasdaq-legn
/

Legend Biotech Corp

LEGN

34.010USD

-1.150-3.27%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.28BMarket Cap

LossP/E TTM



Legend Biotech Corp

34.010

-1.150-3.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

104 / 506

Overall Ranking

205 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

75.786

Target Price

+115.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 436.08% year-on-year.

Overvalued

The company’s latest PE is -19.21, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 89.45M shares, decreasing 22.30% quarter-over-quarter.

Held by Matthews International Capital Management

Star Investor Matthews International Capital Management holds 1.29M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.18.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.28, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 255.06M, representing a year-over-year increase of 36.74%, while its net profit experienced a year-over-year increase of 589.05%.

Score

Industry at a Glance

Previous score

8.28

Change



Financials

6.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.63

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -19.86, which is -0.11% below the recent high of -19.84 and -25.14% above the recent low of -24.85.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.30, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Legend Biotech Corp is 75.00, with a high of 94.00 and a low of 53.12.

Score

Industry at a Glance

Previous score

8.30

Change

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts

Buy

Current Rating

75.786

Target Price

+115.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Legend Biotech Corp

LEGN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.78, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 37.07 and the support level at 32.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

-0.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.260

Neutral

RSI(14)

43.195

Neutral

STOCH(KDJ)(9,3,3)

51.093

Neutral

ATR(14)

1.353

High Vlolatility

CCI(14)

-16.241

Neutral

Williams %R

65.258

Sell

TRIX(12,20)

-0.363

Sell

StochRSI(14)

24.588

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

34.372

Sell

MA10

34.114

Sell

MA20

34.572

Sell

MA50

37.422

Sell

MA100

35.181

Sell

MA200

35.290

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 48.54%, representing a quarter-over-quarter decrease of 2.30%. The largest institutional shareholder is Matthews International Capital Management, holding a total of 1.29M shares, representing 0.70% of shares outstanding, with 8.54% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

11.26M

-3.87%

Westfield Capital Management Company, L.P.

6.92M

+21.07%

HHLR Advisors, Ltd.

5.98M

Suvretta Capital Management, LLC

3.75M

+7.26%

Deerfield Management Company, L.P.

1.74M

+12.36%

BlackRock Institutional Trust Company, N.A.

3.11M

-4.55%

Braidwell LP

2.98M

Fidelity Institutional Asset Management

1.95M

+12.08%

Genscript Biotech Corp

2.25M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.81, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.